Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selitrectinib in NTRK Fusion Cancers
NCT03215511Phase 1Completed
- Sponsor
- Bayer
- Start
- Jul 2017
- Primary completion
- Apr 2022
- Modality
- Small Molecules
- Countries
- 10
01
Overview
Phase 1, open-label trial of selitrectinib in solid tumor (2 arms), sponsored by Bayer. Primary endpoints: Maximum tolerated dose up to 42 days and Recommended dose for further study up to 12 months. Started Jul 2017; status: completed.
02
Drugs
selitrectinib
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT03215511.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03215511.